logiover/clinicaltrials-gov-scraper-sample-data huggingface dataset:
Tociluzumab for Cytokine Release Syndrome With SARS-CoV-2: An Open-Labeled, Randomized Phase 3 Trial
ClinicalTrials.gov ID: NCT04361552
Organization: Emory University
Status: WITHDRAWN
Study type: INTERVENTIONAL
Phases: PHASE3
Conditions: Cerebrovascular Accident
Chronic Obstructive Pulmonary Disease
Chronic Renal Failure
Coronary Artery Disease
Diabetes Mellitus
Malignant Neoplasm
SARS Coronavirus 2 Infection
Interventions: OTHER: Best Practice
BIOLOGICAL: Tocilizumab
Lead sponsor: Emory University (OTHER)
Collaborators: National Cancer Institute (NCI)
Enrollment: 0 participants
Eligibility: sex ALL, minimum age 18 Years, maximum age 
Accepts healthy volunteers: no
Start date: 2020-04-07
Completion date: 2020-06-02
Locations:
facility: Emory University Hospital/Winship Cancer Institute
city: Atlanta
state: Georgia
country: United States

Summary:
This phase III trial compares the effect of adding tocilizumab to standard of care versus standard of care alone in treating cytokine release syndrome (CRS) in patients with SARS-CoV-2 infection. CRS is a potentially serious disorder caused by the release of an excessive amount of substance that is made by cells of the immune system (cytokines) as a response to viral infection. Tocilizumab is used to decrease the body's immune response. Adding tocilizumab to standard of care may work better in treating CRS in patients with SARS-CoV-2 infection compared to standard of care alone.
Effects of Epalrestat on Peripheral Neuropathy and Central Nervous System in Diabetic Patient
ClinicalTrials.gov ID: NCT05184049
Organization: Xiangya Hospital of Central South University
Status: UNKNOWN
Study type: INTERVENTIONAL
Phases: PHASE4
Conditions: Diabetes
Interventions: DRUG: Epalrestat,Mecobalamin
DRUG: Mecobalamin
Lead sponsor: Xiangya Hospital of Central South University (OTHER)
Enrollment: 72 participants
Eligibility: sex ALL, minimum age 18 Years, maximum age 65 Years
Accepts healthy volunteers: no
Start date: 2022-01
Completion date: 2023-10
Locations:
facility: Xiangya Hospital of Central South University
city: Changsha
state: Hunan
country: China

Summary:
This study evaluated the efficacy of epalrestat in diabetic peripheral neuropathy and its effects on the central nervous system in diabetic peripheral neuropathy subjects.
A Phase I, Double-Blind, Randomized, Placebo-Controlled Ascending IV Multiple Dose Tolerance and Pharmacokinetic Study of Trodusquemine (MSI-1436) in Obese or Overweight Type 2 Diabetic Volunteers
ClinicalTrials.gov ID: NCT00806338
Organization: Genaera Corporation
Status: COMPLETED
Study type: INTERVENTIONAL
Phases: PHASE1
Conditions: Diabetes Mellitus
Obesity
Interventions: DRUG: Trodusquemine (MSI-1436)
DRUG: Placebo
Lead sponsor: Genaera Corporation (INDUSTRY)
Enrollment: 22 participants
Eligibility: sex ALL, minimum age 18 Years, maximum age 65 Years
Accepts healthy volunteers: no
Start date: 2008-11
Completion date: 2009-04
Locations:
facility: Cetero Research
city: Miami Gardens
state: Florida
country: United States
facility: dgd Research
city: San Antonio
state: Texas
country: United States

Summary:
The purpose of this study is to evaluate the safety and tolerance of multiple intravenous (through a vein) doses of trodusquemine (MSI-1436) in obese or overweight, type 2 diabetics.
Diabetes Intervention Involving Person-centred Nutritional Education (DINE) - Exploring the Benefits and Challenges of a Person-centred Education on the Nordic Diet for Adults With Type 1 Diabetes.
Acronym: DINE
ClinicalTrials.gov ID: NCT07258758
Organization: Umeå University
Status: RECRUITING
Study type: INTERVENTIONAL
Phases: NA
Conditions: Diabetes Type 1
Interventions: BEHAVIORAL: Dietary intervention
Lead sponsor: Umeå University (OTHER)
Collaborators: Lasarettet i Enköping
Enrollment: 54 participants
Eligibility: sex ALL, minimum age 18 Years, maximum age 
Accepts healthy volunteers: no
Start date: 2025-09-01
Completion date: 2027-06
Locations:
facility: Hospital of Enköping
city: Enköping
state: Uppland
country: Sweden

Summary:
The overall objective for this project is to evaluate the effects of a person-centred education intervention to promote a healthy, sustainable Nordic diet compared with the current practice of providing short dietary information on health outcomes of adults with Type 1 diabetes. The study will measure the intervention's impact on blood glucose levels, blood lipids, blood pressure, and adherence to a sustainable and healthy Nordic diet.

The main question the trial aims to answer is:

Does a person-centred nutritional education have an impact on glucose time in range for adults with Type 1 diabetes, compared with short dietary information?

The participants will:

* Attend either a person-centred nutrition education (intervention) or receive short dietary information (control group).
* Wear their sensor for continuous glucose monitoring (CGM) throughout the trial.
* Visit the clinic for data collection (blood samples and clinical checks) at the start and end of the trial.
* Keep a four-day food diary, fill out a food frequency questionnaire (FFQ) and estimate their food enjoyment at the start and end of the trial.
Personalized Automated Determination of Insulin Pump Setting for Subjects With Type 1 Diabetes Switching From MDI to Pump Therapy and Vice Versa- Safety and Efficacy Feasibility Study
ClinicalTrials.gov ID: NCT03574558
Organization: Rabin Medical Center
Status: COMPLETED
Study type: INTERVENTIONAL
Phases: NA
Conditions: Type1diabetes
Interventions: DEVICE: MD-Logic Switch Advisor
Lead sponsor: Rabin Medical Center (OTHER)
Collaborators: Juvenile Diabetes Research Foundation
Jaeb Center for Health Research
DreaMed
University of Padova
Enrollment: 28 participants
Eligibility: sex ALL, minimum age 6 Years, maximum age 30 Years
Accepts healthy volunteers: no
Start date: 2018-08-01
Completion date: 2019-11-25
Locations:
facility: Schnider children's medical center
city: Petah Tikva
country: Israel

Summary:
The "MD-Logic Switch Advisor" is a software product that is designed to assist in insulin dosage decision making and has two components:

A. MD-Logic Switch Advisor for initiation of pump therapy - this product is designed to assist physicians in decision making when initiating insulin pump therapy.

B. MD-Logic Switch Advisor for patients who use insulin pump therapy and need to switch to MDI (Multiple Daily Injections).

This feasibility study will be divided to two parts:

part A - will include up to 20 patients to evaluate in a feasibility study the switch Advisor from MDI to pump therapy part B - will include up to 20 patients to evaluate in a feasibility study the switch Advisor from pump therapy to MDI The main objective is to evaluate the safety and efficacy of using the MD-Logic Switch Advisor to determine insulin dosing for subjects with type 1 diabetes using pump therapy who wish to switch to from pump to MDI therapy and vice versa.
An Open Label, Three Arm, Pilot Study of the Safety and Clinical Efficacy of Topical Dermacyn™ Wound Care vs. Oral Levofloxacin vs. Combined Therapy for Mild Diabetic Foot Infections
ClinicalTrials.gov ID: NCT00516958
Organization: Oculus Innovative Sciences, Inc.
Status: COMPLETED
Study type: INTERVENTIONAL
Phases: PHASE2
Conditions: Foot Ulcer, Diabetic
Interventions: DRUG: Topical Dermacyn
DRUG: Topical Dermacyn and Levofloxacin
DRUG: Topical Saline and Levofloxacin
Lead sponsor: Oculus Innovative Sciences, Inc. (INDUSTRY)
Enrollment: 65 participants
Eligibility: sex ALL, minimum age 18 Years, maximum age 
Accepts healthy volunteers: no
Start date: 2007-05
Completion date: 2007-12
Locations:
city: Tucson
state: Arizona
country: United States
city: La Jolla
state: California
country: United States
city: Los Angeles
state: California
country: United States
city: San Diego
state: California
country: United States
city: Santa Rosa
state: California
country: United States
city: Denver
state: Colorado
country: United States
city: New Haven
state: Connecticut
country: United States
city: Boca Raton
state: Florida
country: United States
city: Spring Hill
state: Florida
country: United States
city: Evansville
state: Indiana
country: United States
city: Louisville
state: Kentucky
country: United States
city: Boston
state: Massachusetts
country: United States
city: Harrisburgh
state: Pennsylvania
country: United States
city: Hazleton
state: Pennsylvania
country: United States
city: Pittsburgh
state: Pennsylvania
country: United States
city: Salt Lake City
state: Utah
country: United States

Summary:
To compare the rates of clinical success of Topical Dermacyn™ vs. Oral Levofloxacin vs. Combined therapy, in subjects with mild diabetic foot infections in non-ischemic ulcers.
Intensive Versus Conventional Hyperglycemic Control in Hospitalized Non-critically Ill Patients
ClinicalTrials.gov ID: NCT03510078
Organization: Rabin Medical Center
Status: COMPLETED
Study type: INTERVENTIONAL
Phases: NA
Conditions: Diabetes Mellitus
Non-critically Ill Patients
Interventions: DRUG: Insulin
Lead sponsor: Rabin Medical Center (OTHER)
Enrollment: 600 participants
Eligibility: sex ALL, minimum age 18 Years, maximum age 120 Years
Accepts healthy volunteers: no
Start date: 2018-04-17
Completion date: 2025-12-10
Locations:
facility: Rabin Medical Center
city: Petah Tikva
state: Israel
country: Israel
facility: Soroka University Medical Center
city: Beersheba
country: Israel
facility: Rambam Medical Center
city: Haifa
country: Israel
facility: Shamir Medical Center
city: Ẕerifin
country: Israel
facility: Unit of Geriatric Medicine University of Modena and Reggio Emilia, University Hospital of Baggiovara
city: Modena
country: Italy

Summary:
Hyperglycemia is a common condition among hospitalized patients. The occurrence of severe hyperglycemia is associated with increased morbidity and mortality in several populations. Several trials assessed the benefits of aggressive versus conventional glucose control. These studies evaluated different patient populations, glucose targets and treatment protocols and as a result reported conflicting results. To date there are no clear guidelines regarding to the preferred glucose target range in hospitalized non-critically ill patients. The common practice is to maintain glucose level lower than 180 mg/dl however there are no evidence based regarding to the outcomes of hospitalized patients treated with intensive compared to conventional glycemic control. This prospective randomized controlled study will compare intensive vs. standard glycemic control in hospitalized non-critically ill patients.

Within 24 hours of hospitalization in the internal medical or geriatric departments, patients who are expected to require hospitalization for at least three consecutive days will be randomly assigned into one of the two study groups - intensive with a target blood glucose range of 130 mg per deciliter or less, or conventional glucose control, with a target of 130-180 mg per deciliter. The investigators defined the primary end point as a composite outcome of mortality in 30 days, severe hypoglycemia, severe infections within 30 days, CVA and cardiac ischemic events within 30 days.
Translating Information on Comparative Effectiveness Into Practice (TRICEP)
Acronym: TRICEP
ClinicalTrials.gov ID: NCT01293578
Organization: Mayo Clinic
Status: COMPLETED
Study type: INTERVENTIONAL
Phases: NA
Conditions: Type 2 Diabetes Mellitus
Interventions: OTHER: Diabetes Medication Choice Cards
Lead sponsor: Mayo Clinic (OTHER)
Enrollment: 550 participants
Eligibility: sex ALL, minimum age 18 Years, maximum age 
Accepts healthy volunteers: yes
Start date: 2011-01
Completion date: 2015-06
Locations:
facility: Albert Lea Medical Center
city: Albert Lea
state: Minnesota
country: United States
facility: Mayo Clinic Kasson
city: Kasson
state: Minnesota
country: United States
facility: Mayo Clinic Health System- Immanual St. Joseph's
city: Mankato
state: Minnesota
country: United States
facility: Hennepin County Medical Center
city: Minneapolis
state: Minnesota
country: United States
facility: Park Nicollet Institute
city: Saint Louis Park
state: Minnesota
country: United States
facility: Mayo Clinic Health System-Franciscan Healthcare
city: La Crosse
state: Wisconsin
country: United States

Summary:
The goal of this study is to test the relative merits of a decision aid for diabetes medications that we have developed - Diabetes Medication Choice Cards- versus usual care in translating comparative effectiveness research (CER) into real world clinics. This study will involve about 20 primary care practice sites affiliated with Mayo Health System, Park Nicollet, or Hennepin County Medical Center. There will be no recruiting done at the Mayo Clinic.
The Impact of Glycation Modification of apoA-I on HDL Function and Atherogenesis in Type Diabetes Mellitus
ClinicalTrials.gov ID: NCT05659043
Organization: Ruijin Hospital
Status: UNKNOWN
Study type: OBSERVATIONAL
Conditions: Diabetes Mellitus, Type 2
Interventions: OTHER: overnight fasting
Lead sponsor: Ruijin Hospital (OTHER)
Enrollment: 2000 participants
Eligibility: sex ALL, minimum age 18 Years, maximum age 90 Years
Accepts healthy volunteers: no
Start date: 2017-01
Completion date: 2023-12
Locations:
facility: Ruijin Hospital, Shanghai Jiaotong University School of Medicine
city: Shanghai
state: Shanghai Municipality
country: China

Summary:
The goal of this study is to determine the relationship of apoprotein A-1 (apoA-I) glycation and development of diabetic atherosclerosis.

ApoA-I is crucial for reverse cholesterol transport and anti-inflammation/anti-atherosclersis functions of HDL. However, apoA-I is easily subjected to non-enzymatic glycation modification in diabetic milleu. Our preliminary study has shown that apoA-I in HDL from type 2 diabetes mellitus (T2DM) patients with coronary artery disease (CAD) is significantly glycated, and site specific glycation of apoA-I impairs HDL function and is related to the development of atherosclerosis. To the best of our knowledge, less clinical information regarding apoA-I glycation and CAD has been reported. In this cross-sectional study, by consecutively enrolling diabetic patients with (two to three hundred) or without CAD (controls, six to eight hundred) in our hospital, we will isolate their serum HDL and perform a qualitative and quantitative proteomic analysis of apoA-I glycation. The relation of apoA-I glycation and HDL function and angiography-determined severity of CAD will be evaluated. Later, we will follow these diabetic patients to analyze the influence of apoA-I glycation on the outcome including plaque progression.
Risk of Hypoglycemia in the Transition From Inpatient to Outpatient Setting. Comparative Study of Basal-bolus Insulin Versus Basal Insulin Plus GLP-1 Analogue
ClinicalTrials.gov ID: NCT05767255
Organization: Hospital Universitario San Ignacio
Status: UNKNOWN
Study type: INTERVENTIONAL
Phases: PHASE3
Conditions: Diabetes Mellitus, Type 2 Treated With Insulin
Interventions: DRUG: insulin degludec + liraglutide
DRUG: Insulin Glargine - Insulin Aspart
Lead sponsor: Hospital Universitario San Ignacio (OTHER)
Enrollment: 66 participants
Eligibility: sex ALL, minimum age 18 Years, maximum age 
Accepts healthy volunteers: no
Start date: 2022-12-01
Completion date: 2023-08-30
Locations:
facility: Hospital Universitario San Ignacio
city: Bogotá
country: Colombia

Summary:
The association of insulin degludec with liraglutide in the same device (IDegLira) is a potent but at the same time safe drug that reduces the risk of hypoglycemia when compared to a basal or basal-bolus insulin schedule.

The DUAL (Dual Action of Liraglutide and Insulin Degludec) studies are the pivotal studies of this combination. Specifically, the DUAL VII study has demonstrated that ideglira is a non-inferior drug in terms of glycemic control versus a basal-bolus schedule in patients in the outpatient setting who have failed basal insulin.

Although the basal-bolus insulin plus correction schedule is frequently used in hospitalized patients with hyperglycemia, outpatient management with a complex insulin schedule creates challenges that are difficult to mitigate due to limited time for patient education during an acute illness and limited access to the physician responsible for post-discharge diabetes management.

The use of IDegLira has not been evaluated in clinical studies in the hospital discharge setting where the authors believe it has great potential because it offers similar potency to the basal-bolus scheme but with greater safety with respect to hypoglycemia and less complexity for the patient because it is associated with fewer applications and less need for capillary self-monitoring.

For this reason, in the hospital-home transition scenario, ideglira therapy in patients with poor metabolic control and requiring intensification therapy is proposed as an alternative to the basal-bolus scheme.
Ultrasound Evaluation of Gastric Content in Diabetic and Non-Diabetic Term Pregnant Women: An Observational Study
ClinicalTrials.gov ID: NCT05959135
Organization: Sisli Hamidiye Etfal Training and Research Hospital
Status: COMPLETED
Study type: OBSERVATIONAL
Conditions: Gastric Ultrasonography
Gastric Volume
Pulmonary Aspiration
Diabetic Pregnancy
Fasting
Interventions: DEVICE: Gastric ultrasonography
Lead sponsor: Sisli Hamidiye Etfal Training and Research Hospital (OTHER)
Enrollment: 80 participants
Eligibility: sex FEMALE, minimum age 18 Years, maximum age 40 Years
Accepts healthy volunteers: yes
Start date: 2023-07-26
Completion date: 2023-12-25
Locations:
facility: Sisli Hamidiye Etfal Training and Research Hospital
city: Sarıyer
state: Istanbul
country: Turkey (Türkiye)

Summary:
Perioperative aspiration is particularly concerning in pregnant women due to anatomical changes. To mitigate this risk, pre-anesthetic fasting is recommended, with varying guidelines. Gastric ultrasound can non-invasively assess stomach contents, and mathematical models help estimate stomach volumes using the gastric antral cross-sectional area (CSA).

This study aims to compare CSA and estimated gastric volumes through ultrasound in fasting diabetic and non-diabetic pregnant women scheduled for cesarean section, as diabetes may affect stomach fullness. Additionally, it will investigate the relation between demographic and clinical variables and CSA values.

This research can shed light on diabetes' influence on aspiration risk in pregnancy and evaluate fasting guidelines, underscoring the significance of gastric ultrasound.
EFFICACY OF DIACEREIN ADDITION ON INTERLEUKIN-1Β, HS-CRP, TNF-Α LEVELS AND GLYCEMIC CONTROL IN UNCONTROLLED TYPE 2 DIABETES MELLITUS PATIENTS AT DR. MOHAMMAD HOESIN GENERAL HOSPITAL PALEMBANG
ClinicalTrials.gov ID: NCT06912035
Organization: Universitas Sriwijaya
Status: COMPLETED
Study type: INTERVENTIONAL
Phases: PHASE2
PHASE3
Conditions: Uncontrolled Diabetes
Diabetes Mellitus Type 2
Interventions: DRUG: Diacerein 50 mg Capsule
DRUG: Placebo
Lead sponsor: Universitas Sriwijaya (OTHER)
Collaborators: Indonesia Endowment Fund for Education (LPDP), Ministry of Finance Republik of Indonesia
Enrollment: 34 participants
Eligibility: sex ALL, minimum age 60 Years, maximum age 60 Years
Accepts healthy volunteers: no
Start date: 2024-06-21
Completion date: 2024-11-08
Locations:
facility: Universitas Sriwijaya
city: Palembang
state: South Sumatera
country: Indonesia

Summary:
The goal of this clinical trial is to learn if diacerein supplementation can help improve inflammation and glycemic control in adults with uncontrolled type 2 diabetes. It will also study the safety and tolerability of diacerein. The main questions it aims to answer are:

* Does diacerein lower levels of inflammatory markers like interleukin-1β, hs-CRP, and TNF-α?
* Does diacerein improve blood sugar control?
* What side effects or problems do participants have when taking diacerein?

Researchers will compare diacerein to a placebo (a look-alike substance with no active drug) to see if it works better for managing type 2 diabetes.

Participants will:

* Be adults aged 40-60 with uncontrolled type 2 diabetes
* Take either diacerein or a placebo every day for 12 weeks
* Visit the clinic for blood tests and monitoring at the beginning and end of the trial
* Be evaluated for side effects and medication adherence\]
Sugar Text: A Randomized Controlled Trial of a Text Message Intervention for Women With Diabetes in Pregnancy
Acronym: Sugar Text
ClinicalTrials.gov ID: NCT01973374
Organization: University of Pennsylvania
Status: COMPLETED
Study type: INTERVENTIONAL
Phases: NA
Conditions: Diabetes in Pregnancy
Gestational Diabetes
Texting Interventions
Interventions: BEHAVIORAL: Text Message Intervention
Lead sponsor: University of Pennsylvania (OTHER)
Enrollment: 30 participants
Eligibility: sex FEMALE, minimum age 18 Years, maximum age 50 Years
Accepts healthy volunteers: no
Start date: 2013-01
Completion date: 2014-04
Locations:
facility: Hospital of the University of Pennsylvania
city: Philadelphia
state: Pennsylvania
country: United States

Summary:
Maternal diabetes in pregnancy can negatively impact fetal well-being and contribute to adverse pregnancy outcomes. Much of the morbidity associated with diabetes in pregnancy can be minimized with tight glucose control. A number of studies in non-pregnant populations have highlighted the feasibility, acceptability and efficacy of text messaging interventions for improving diabetic compliance and control. This study will investigate whether a text messaging intervention is feasible and effective in an urban, diabetic, obstetric clinic and whether this intervention can improve compliance with diabetes care, glucose control and pregnancy outcomes. The study will also assess satisfaction with the intervention itself.
Short and Long Term Effects of a Dypeptidil-peptidase-4 Versus Bedtime NPH Insulin as add-on Therapy in Patients With Type 2 Diabetes
ClinicalTrials.gov ID: NCT02607410
Organization: University of Sao Paulo General Hospital
Status: COMPLETED
Study type: INTERVENTIONAL
Phases: PHASE4
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG: sitagliptin
DRUG: NPH insulin
Lead sponsor: University of Sao Paulo General Hospital (OTHER)
Collaborators: Fundação de Amparo à Pesquisa do Estado de São Paulo
Enrollment: 40 participants
Eligibility: sex ALL, minimum age 35 Years, maximum age 70 Years
Accepts healthy volunteers: no
Start date: 2010-01
Completion date: 2014-07
Locations:
facility: University of Sao Paulo General Hospital
city: São Paulo
state: São Paulo
country: Brazil

Summary:
To compare the short and long term effects of inhibitor of the DPP-IV enzyme, sitagliptin , with bedtime NPH insulin in patients with T2D inadequately controlled with sulphonylurea plus biguanide: effects on beta cell function and on metabolic profile.
Evaluation of Correlations Between Volatile Organic Compounds (VOCs) Spectra Measured With GC-IMS and MOx-sensors and Venous Blood Glucose in Subjects With Type 2 Diabetes
Acronym: Evo
ClinicalTrials.gov ID: NCT07147010
Organization: DCB Research AG
Status: COMPLETED
Study type: INTERVENTIONAL
Phases: NA
Conditions: Type 2 Diabetes
Interventions: DEVICE: MIB Breath Analyzer
Lead sponsor: DCB Research AG (OTHER)
Collaborators: Insel Gruppe AG, University Hospital Bern
BOYDSENSE
Enrollment: 20 participants
Eligibility: sex ALL, minimum age 45 Years, maximum age 70 Years
Accepts healthy volunteers: no
Start date: 2024-10-01
Completion date: 2025-11-27
Locations:
facility: Inselspital Bern
city: Bern
country: Switzerland

Summary:
The goal of this study is to evaluate correlations between VOCs in the breath and venous blood glucose values in various glycaemic states in people living with Type 2 Diabetes.

VOCs are measured with a gold-standard GC-IMS device and a prototype of a novel breath analyzer. Participants will be exposed to different blood glucose levels at different rates of change by administering glucose solution and insulin and by a meal challenge.